What is Robocath?
Founded in 2009 and headquartered in Rouen, France, Robocath designs and commercializes robotic systems tailored for cardiovascular disease treatment. The company's flagship innovation, the R-One system, provides a robotic-assisted approach to coronary angioplasty, offering a sophisticated interface that complements manual surgical techniques. With CE marking achieved in 2019, the technology has demonstrated significant clinical efficacy, reporting 100% technical success in pre-clinical trials. By maintaining an open architecture, Robocath ensures its systems are compatible with existing cath lab infrastructure, facilitating seamless adoption for healthcare providers across Europe and Africa. The firm is currently scaling its operations to address the growing demand for remote vascular emergency treatments.
How much funding has Robocath raised?
Robocath has raised a total of $56.3M across 3 funding rounds:
Series A
$7.6M
Series B
$5.3M
Series C
$43.4M
Series A (2017): $7.6M with participation from M Capital Advisors, Cardio Participation, Normandie Participations, GO Capital, and Groupe Credit Agricole
Series B (2019): $5.3M led by Go Capital, M Capital, NCI, Supernova Invest, and Normandie Participations
Series C (2020): $43.4M supported by Anaxago, Zhejiang Silk Road Fund, CS Group, MicroPort Scientific Corporation, and TUS-Holdings
Key Investors in Robocath
GO Capital
A venture capital firm focused on high-growth technology companies, providing strategic support for market penetration and international scaling.
NCI
A prominent regional private equity firm specializing in the development and transfer of businesses, with a strong focus on supporting SMEs and startups in France.
Supernova Invest
A deeptech-focused investment firm that provides patient capital and operational expertise to high-growth companies in the healthcare and industrial technology sectors.
What's next for Robocath?
With the infusion of capital from its latest funding rounds, Robocath is poised to transition from a regional innovator to a global leader in vascular robotics. The strategic focus remains on expanding the clinical footprint of the R-One system and advancing research into remote-controlled vascular interventions. As the company continues to refine its technological ecosystem, it is expected to leverage its strong investor base to navigate complex regulatory landscapes and penetrate new international markets. The ongoing commitment to safety and procedural efficiency positions Robocath to redefine the standard of care in interventional cardiology, potentially reducing the physical burden on surgeons while improving long-term patient outcomes.
See full Robocath company page
